From the Research
There is no established contraindication between Eliquis (apixaban) and glucosamine supplements, but caution is warranted due to the potential for increased bleeding risk. Eliquis is an anticoagulant medication that prevents blood clots by inhibiting Factor Xa in the coagulation cascade, while glucosamine is a dietary supplement commonly used for joint health. Some limited evidence suggests glucosamine might have mild antiplatelet effects, which theoretically could enhance the blood-thinning effects of Eliquis, potentially increasing bleeding risk 1. This interaction is not well-documented in clinical studies and is generally considered minor.
Key Considerations
- Patients taking Eliquis who wish to use glucosamine should discuss this combination with their healthcare provider before starting the supplement.
- It's particularly important for those with additional bleeding risk factors or who take other medications affecting blood clotting.
- Any unusual bleeding or bruising while taking this combination should prompt immediate medical attention.
- Regular monitoring of anticoagulation status may be advisable when starting or stopping glucosamine while on Eliquis therapy.
Evidence Review
The most recent and relevant study on apixaban interactions is from 2020, which highlights the potential for drug-drug interactions, including those that may impair hemostasis 1. However, there is no specific mention of glucosamine in this study. Other studies, such as the 2017 quick reference guide to apixaban, provide an overview of the medication's use and safety profile, but do not address the specific interaction with glucosamine 2.
Clinical Implications
In clinical practice, the decision to use glucosamine in patients taking Eliquis should be made on a case-by-case basis, taking into account the individual patient's risk factors and medical history. Patients should be closely monitored for signs of bleeding or other adverse effects, and alternative treatments for joint health should be considered if necessary.